




Somapacitan

Revised: September 20, 2021.

CASRN: 1338578-34-9



Drug Levels and Effects

Summary of Use during Lactation

Because somapacitan is a large molecule that is poorly absorbed orally, it is not likely to reach the bloodstream of the infant or cause any adverse effects in breastfed infants. However, there is no published experience with somapacitan during breastfeeding, so an alternate drug may be preferred, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date. However, the closely related recombinant human growth hormone, somatropin, has been reported to increase milk production.

Alternate Drugs to Consider

Somatropin

Substance Identification

Substance Name

Somapacitan

CAS Registry Number

1338578-34-9

Drug Class

Breast Feeding

Lactation

Human Growth Hormone